All In Biotech

Drug Trial Radar · NCT03934307

A Study to Evaluate ALN-AGT01 in Patients With Hypertension

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Single Dose and Active Comparator-Controlled Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered ALN-AGT01 in Patients With Hypertension

Last checked: Nov 20, 2026Latest source record: Jan 17, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 124 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

124

Actual

Start

May 1, 2019

Primary completion

Apr 20, 2022

Study completion Jan 4, 2023

Sponsor

Lead sponsor
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
Sponsor type
Industry
First posted
May 1, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) effects of subcutaneous (SC) ALN-AGT01 (zilebesiran) in participants with hypertension. The study will be conducted in 4 parts: Part A will be a single ascending dose (SAD) phase in hypertensive participants, Part B will be a single dose (SD) phase in hypertensive participants with controlled salt intake, Part D will be a MD phase in hypertensive participants who are obese, and Part E will be an open-label SD phase with co-administration of irbesartan in hypertensive patients.

Conditions

  • Hypertension

Interventions

  • ALN-AGT01Drug

    ALN-AGT01 will be administered by subcutaneous (SC) injection.

  • ALN-AGT01-Matching PlaceboDrug

    Normal saline (0.9% NaCl) matching volume of ALN-AGT01 doses will be administered SC.

  • IrbesartanDrug

    Irbesartan will be administered orally.

  • Irbesartan-Matching PlaceboDrug

    Irbesartan-matching placebo will be administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Adverse Events (AEs)Time frame: Parts A, B and E: each up to approximately 12 months; Part D: up to approximately 18 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Clinical Trial Site

    Edinburgh, United Kingdom

  • Clinical Trial Site

    London, United Kingdom

  • Clinical Trial Site

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.